Alyson Muldrew
Overview
Explore the profile of Alyson Muldrew including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
172
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gholami S, Scheppke L, Kshirsagar M, Wu Y, Dodhia R, Bonelli R, et al.
JAMA Ophthalmol
. 2024 Feb;
142(3):226-233.
PMID: 38329740
Importance: Deep learning image analysis often depends on large, labeled datasets, which are difficult to obtain for rare diseases. Objective: To develop a self-supervised approach for automated classification of macular...
2.
Ferrara M, Rivera-Real A, Hillier R, Habib M, Kadhim M, Sandinha M, et al.
Graefes Arch Clin Exp Ophthalmol
. 2022 Dec;
261(6):1553-1562.
PMID: 36512088
Purpose: To assess study design and a range of anatomical and functional changes after internal limiting membrane (ILM) peeling using forceps developed for atraumatic ILM pick-up compared to standard forceps....
3.
Peto T, Evans R, Reeves B, Harding S, Madhusudhan S, Lotery A, et al.
Ophthalmol Retina
. 2022 Mar;
6(8):664-675.
PMID: 35314388
Purpose: To describe the frequency of long-term morphologic features and their relationships with visual function in participants who exited the Inhibition of VEGF in Age-Related Choroidal Neovascularisation (IVAN; ISRCTN92166560) trial....
4.
Mehta A, Steel D, Muldrew A, Peto T, Reeves B, Evans R, et al.
Am J Ophthalmol
. 2021 Oct;
236:89-98.
PMID: 34626573
Purpose: To compare demographics, visual acuity (VA) and retinal morphology between those with, and without baseline submacular hemorrhage (SMH) for patients enrolled in the Inhibit VEGF in Age-related Choroidal Neovascularization...
5.
Mendonca L, Perrott-Reynolds R, Schwartz R, Madi H, Cronbach N, Gendelman I, et al.
Ophthalmology
. 2020 Dec;
128(7):1109-1112.
PMID: 33359557
No abstract available.
6.
Evans R, Reeves B, Maguire M, Martin D, Muldrew A, Peto T, et al.
JAMA Ophthalmol
. 2020 Aug;
138(10):1043-1051.
PMID: 32816002
Importance: When initiating anti-vascular endothelial growth factor (VEGF) treatment for patients with neovascular age-related macular degeneration (nAMD), knowledge of prognostic factors is important for advising patients and guiding treatment. We...
7.
Jackson T, Soare C, Petrarca C, Simpson A, Neffendorf J, Petrarca R, et al.
JAMA Ophthalmol
. 2020 Jul;
138(8):835-842.
PMID: 32644148
Importance: Although anti-vascular endothelial growth factor (VEGF) treatment offers better outcomes than the natural history of neovascular age-related macular degeneration (ARMD), a less burdensome, less expensive, and more durable treatment...
8.
Quinn N, Steel D, Chakravarthy U, Peto T, Hamill B, Muldrew A, et al.
Ophthalmol Retina
. 2020 Apr;
4(8):801-813.
PMID: 32335034
Purpose: To describe the prevalence of vitreomacular interface (VMI) features and their associated risk factors in the Northern Ireland Cohort for the Longitudinal Study of Ageing (NICOLA) Study. Design: Cross-sectional...
9.
Freiberg F, Michels S, Muldrew A, Slakter J, OShaughnessy D, Czeszynski A, et al.
Br J Ophthalmol
. 2018 Jun;
103(4):469-474.
PMID: 29930098
Purpose: To report the incidence and features of retinal microvascular abnormalities (MVAs) occurring secondary to stereotactic radiotherapy (SRT) in a randomised double-masked sham-controlled clinical trial at 21 European sites. Methods:...
10.
Reeves B, Scott L, Taylor J, Hogg R, Rogers C, Wordsworth S, et al.
Health Technol Assess
. 2016 Nov;
20(80):1-120.
PMID: 27809956
Background: Patients with neovascular age-related macular degeneration (nAMD) usually attend regular reviews, even when the disease is quiescent. Reviews are burdensome to health services, patients and carers. Objectives: To compare...